ES2544780T3 - Metadoxina para su uso como inhibidor de fibrosis hepática - Google Patents

Metadoxina para su uso como inhibidor de fibrosis hepática Download PDF

Info

Publication number
ES2544780T3
ES2544780T3 ES10712519.7T ES10712519T ES2544780T3 ES 2544780 T3 ES2544780 T3 ES 2544780T3 ES 10712519 T ES10712519 T ES 10712519T ES 2544780 T3 ES2544780 T3 ES 2544780T3
Authority
ES
Spain
Prior art keywords
metadoxine
liver fibrosis
fibrosis inhibitor
inhibitor
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10712519.7T
Other languages
English (en)
Inventor
Massimo Baldacci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratori Baldacci SpA
Original Assignee
Laboratori Baldacci SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratori Baldacci SpA filed Critical Laboratori Baldacci SpA
Application granted granted Critical
Publication of ES2544780T3 publication Critical patent/ES2544780T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Metadoxina para su uso en el tratamiento de la fibrosis hepática, caracterizada porque dicha metadoxina es para ser administrada por vía oral a un ser humano.

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES10712519.7T 2009-03-06 2010-03-04 Metadoxina para su uso como inhibidor de fibrosis hepática Active ES2544780T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2009A000333A IT1393338B1 (it) 2009-03-06 2009-03-06 Uso terapeutico della metadoxina come inibitore della fibrosi epatica.
ITMI20090333 2009-03-06
PCT/IB2010/050930 WO2010100619A1 (en) 2009-03-06 2010-03-04 Metadoxine for use as inhibitor of hepatic fibrosis

Publications (1)

Publication Number Publication Date
ES2544780T3 true ES2544780T3 (es) 2015-09-03

Family

ID=41202480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10712519.7T Active ES2544780T3 (es) 2009-03-06 2010-03-04 Metadoxina para su uso como inhibidor de fibrosis hepática

Country Status (6)

Country Link
US (1) US20120029031A1 (es)
EP (1) EP2403495B1 (es)
ES (1) ES2544780T3 (es)
IT (1) IT1393338B1 (es)
PT (1) PT2403495E (es)
WO (1) WO2010100619A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061743A1 (en) * 2009-11-18 2011-05-26 Alcobra Ltd. Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders
KR20150063040A (ko) * 2012-09-26 2015-06-08 유로드러그 레버러토리즈 비. 브이. 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제
CA2915585C (en) * 2014-12-19 2023-05-23 John Rovnan Systems and methods for managing an electronic database

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) * 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
KR100877600B1 (ko) * 2006-11-30 2009-01-08 재단법인서울대학교산학협력재단 메타독신 및 마늘유를 유효성분으로 함유하는 알코올성지방간 및 지방간성 간염의 예방 및 치료용 약학 조성물

Also Published As

Publication number Publication date
PT2403495E (pt) 2015-09-17
IT1393338B1 (it) 2012-04-20
ITMI20090333A1 (it) 2010-09-07
EP2403495A1 (en) 2012-01-11
WO2010100619A1 (en) 2010-09-10
US20120029031A1 (en) 2012-02-02
EP2403495B1 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2540751T3 (es) Composición para mejorar la función sexual masculina que contiene extracto de baya de ginseng
ES2661582T3 (es) Efecto antiinflamatorio de la celulosa microfibrilada
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
ECSP12011935A (es) Triazolopiridinas
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
CR20110340A (es) Compuestos purina
GT201100205A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
CU20120171A7 (es) Triazolopiridinas sustituidas
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
DOP2013000244A (es) Triazolopiridinas
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
ES2531516T3 (es) Uso de escina
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
ES2508165T3 (es) Lactoferrina y sustancia blanca
ES2508117T3 (es) Uso del butanoato de 4-[etil(dimetil)amonio)] en el tratamiento de la enfermedad cardiovascular